EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH 1 30 March 2023 2 EMA/CHMP/83033/2023 3 Committee for Medicinal Products for Human Use (CHMP) 4 Questions and answers on data requirements when 5 replacing hydrofluorocarbons as propellants in oral 6 pressurised metered dose inhalers 7 8 Agreed by Rheumatology and Immunology Working Party February 2023 Adopted by CHMP for release for consultation 30 Mar 2023 Start of public consultation April 2023 End of consultation (deadline for comments) 9 10 31 May 2023 Comments should be provided using this template.

UNIVERSITY HOSPITAL RHEINISCH-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN CLINIC FOR GENERAL, VISCERAL AND TRANSPLANT SURGERY Director: University Professor Dr. med.

EFCTC EFCTC POSITION PAPER August 2021 Published evidence supports very low yield of TFA from most HFOs and HCFOs Summary EFCTC has analysed the most current, peer reviewed scientific papers on the potential contribution of HFOs and HCFOs, containing the CF3CH= moiety, to existing and future TFA levels.

Classification: General Business Use SHPP's Inputs to the Public Consultation Comments to Annex XV PFAS Restriction Proposal Question number 6: Missing uses: PTFE Used in Internally Lubricated Thermoplastic Compounds Previous ECHA Submission Ref.: Comment Ref. 3981 Executive Summary SABIC's Specialties business (SHPP) produces a range of highly differentiated products, including high-performance thermoplastics, compounds, and additives that meet complex thermal, mechanical, optical, and electrical property requirements.

July 31, 2020 Comments for call for evidence on PFASs Dear Sirs and Madams: On behalf of Japan Cosmetic Industry Association (JCIA) representing interest of more than one thousand Japanese cosmetic companies, I would like to express my sincere gratitude to your great efforts to tackle the emerging issues such as PFASs to protect and preserve the global environment.

W.

GROUPE SEB W Mise en danger de l'emploi et de la competitivite pour le groupe SEB en France et en Europe PPL n514 2023-2024 EELV 3 al \' y o a= : : | a SEB Proposition de loi soumise au Snat enpremerelecture 4 Le Groupe SEB rsolument engag en France depuis toujours. 9 Pourquoi dfendre l'usage desfluoropolymeres 2... 10 Principales diffrences entre les PFAS proccupants et les fluoropolymres 13 INNOCUItE dU PTFE oo 14 Critre d'usage essentiel.

PM 2022 Dnr nr 2021/04303 Vetenskapligt underlag fr PFAS i dricksvatten _______________ Denna titel kan laddas ner frn: Livsmedelsverkets publikationer Citera grna Livsmedelsverkets texter, men glm inte att uppge kllan.

TECHNICAL REPORT: Analysis of alternatives to fluoropolymers and potential impacts related to substitution in different sectors of use Version 1 19 July 2022 Disclaimer The authors do not accept any liability with regard to the use that may be made of the information contained in this document.

HONEYWELL ADVANCED LIMITED RIVERVIEW HOUSE HARVEY'S QUAY APARTMENTS LIMERICK V94R3DE IRELAND 27June 2023 PFAS REACH Annex XV Restriction Report 1ST Public Consultation (22 March - 25 September 2023) Request for Exclusion or Derogation of pMDIs Propellants from PFAS REACH Restriction Proposal Executive summary Honeywell International Inc.

Comment on Proposed Restriction of PFAS Jul 31, 2023 Japan Valve Manufacturers' Association (JVMA) Japan Valve Manufacturers Association (JVMA) appreciates the opportunity to provide comments to the PFAS restriction proposal. 1.

2966029 @plasticseurope.org]; @outlook.com] Wl @baua.bund.dej; @agcce.com' @agcce.com]; Sent: Subject: Tue 1/5/2021 12:09:54 PM RE: Consultation on Proposed Comprehensive Restriction/Ban for All Per and Polyfluoroalkyl (PFAS) Substances Received: Tue 1/5/2021 12:09:55 PM letter to Cefic Plastics Europe 050121.pdf IE=E IEE oer Best wishes for 2021.

Boba.Egat @miiodir.no IEEE @nijodirng); 2966075 Sent: Sat 4/27/2024 11:20:50 PM Subject: RE: Request for meeting with Syensqo on Universal PFAS Restriction Received: Sat 4/27/2024 11:20:51 PM Hi and all, We received the exact same request.

From: Sent: Subject: Received: IEEE @ 2s.cor; EKER @ iv.nl; restrictiePFAS] )[ 5.1.2i @rivm.nl] 2965702 RET si com; INEXECE INERECIN 5.1.2e @minezk.nl] Thur 6/22/2023 2:31:51 PM RE: Contactgegevens betrokkenen PFAS Thur 6/22/2023 2:32:02 PM RES Geachte heer Bij deze maak ik u graag nogmaals attent op onderstaande e-mail.

ELSEVIER Regulatory Toxicology and Pharmacology 134 (2022) 105226 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts J.K.